MedTrace Logo

Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC

NCT07783659 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-08-25

No results posted yet for this study

Summary

To find the optimal (best) recommended dose of zotatifin and carboplatin to treat patients with metastatic or recurrent TNBC.

Conditions

  • Phase IB
  • Zotatifin
  • EIF4A
  • Advanced TNBC
  • Platinum Helix Inhibition

Interventions

DRUG

Zotatifin

Given by IV

DRUG

carboplatin

Given by IV

Sponsors & Collaborators

  • Cancer Prevention Research Institute of Texas

    collaborator OTHER

  • SJP Biotec

    collaborator UNKNOWN

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Bora Lim, MD · UT MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-02-12
Primary Completion
2030-06-30
Completion
2032-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07783659 on ClinicalTrials.gov